Welcome to the European Association for Cancer Research
Connecting cancer researchers together
Overactivation of Oncogenic Signalling as a Potential Cancer Treatment Strategy
Virtual Event : 20 - 21 January 2026
Scientific programme
To download and print the programme, use the links below.
Listed times are in Central European Time (CET)
WELCOME TO DAY ONE
Chair: Rene Bernards
Matheus Dias NKI, Netherlands
'Therapeutic OVERactivation of oncogenic signalling as a cancer treatment strategy'
Q&A: 12:25-12:35
Chrysa Papagianni Netherlands Cancer Institute, Netherlands
Proffered Paper 1: 'Overactivation of oncogenic signaling steers cancer cells towards less malignant phenotypes'
Q&A: 12:45-12:50
Dylan Farnsworth BC Cancer Research Institute, Canada
Proffered Paper 2: 'Disrupting proteostasis potentiates ERK hyperactivation in LUAD'
Q&A: 13:00-13:05
Vesselina Cooke Novartis, USA
'Small Molecule-induced ERK Hyperactivation as a Novel Therapeutic Approach for BRAF V600-Mutant Melanoma'
Q&A: 13:25-13:35
REFRESHMENT BREAK
Chair: Bart Vanhaesebroeck
FLASH TALKS 1
A selection of high-scoring abstracts presented as 3 minute flash talks.
Monica Roman-Trufero Lausanne University Hospital, Switzerland
Proffered Paper 3: 'GCN2 loss drives translational overdrive and metabolic collapse, creating a targetable cancer vulnerability'
Q&A: 14:15-14:20
Arun Unni Weill Cornell Medicine, USA
'Understanding the consequences of excess RAS pathway activity in cancer cells'
Q&A: 14:40-14:50
REFRESHMENT BREAK
Pia Giovannelli University of Campania Luigi Vanvitelli, Italy
Proffered Paper 4: 'Androgen Receptor Paradox: Overactivation of ERK Inhibits HRPC Growth'
Q&A: 15:15-15:20
Marta Rubin University of Turin, Italy
Proffered Paper 5: 'Hyperactivation of ALK signaling triggered by PTPN2/PTPN1 pharmacologic inhibition induces oncogenic stress responses to promote tumor eradication in ALK-positive lymphoma'
Q&A: 15:30-15:35
Closing Keynote
Markus Müschen Yale School of Medicine, USA
'Hyperactivation of oncogenic STAT5-signaling as treatment strategy for tyrosine kinase-driven leukemia'
Q&A: 16:05-16:20
SUMMARY AND CLOSE
Listed times are in Central European Time (CET)
WELCOME TO DAY TWO
Chair: Bart Vanhaesebroeck
Benoit Bilanges UCL Cancer Institute, UK
'Pharmacological activation of PI3Kα triggers cancer cell death under metabolic stress'
Q&A: 12:25-12:35
Marina Baessa IPATIMUP / i3s, Portugal
Proffered Paper 6: 'Therapeutic T-cell receptor activation in T-cell acute lymphoblastic leukemia'
Q&A: 12:45-12:50
Eunice Cho The Broad Institute, USA
'Directed clonal evolution: Exploiting divergent MAPK inhibitor resistance for convergent hypersensitivity to MAPK hyperactivation'
Q&A: 13:10-13:20
REFRESHMENT BREAK
FLASH TALKS 2
A selection of high-scoring abstracts presented as 3 minute flash talks.
David Santamaria CIC (Cancer Research Center of Salamanca), Spain
Proffered Paper 7: 'MAPK hyper-signalling driven by DUSP4 inactivation modulates the onset and progression of KRAS mutant lung adenocarcinoma'
Q&A: 14:00-14:05
Andrew Intlekofer MSKCC, USA
'Enzyme hyperactivation to target oncometabolism'
Q&A: 14:25-14:35
REFRESHMENT BREAK
Chair: Rene Bernards
Ana Banito German Cancer Research Center (DKFZ), Germany
Proffered Paper 8: 'A dynamic balance between vPRC1 complexes finetunes oncofusion activity in synovial sarcoma'
Q&A: 15:00-15:05
Closing Keynote
Kimberly Stegmaier Dana-Farber Cancer Institute, USA
'EWS::FLI1 Activation Lethality in Ewing Sarcoma'
Q&A 15:35-15:50
DISCUSSION SESSION
Will over activation cause cancer or cure cancer?
CONFERENCE SUMMARY AND CLOSE
Key dates
Abstract submission deadline:
17 November 2025
Registration and Payment deadline:
07 January 2026
